Founding Partner,
Paul Lelieveld,
Ir., MSc.

Paul’s experience spans more than 25 years in the commercialization of technologies, strategy & business development, M&A, and in selecting, investing and building LifeScience companies; Paul has successfully led investment rounds in several Life science companies for investment funds and family offices.

Founding Partner
Frans van Dalen,
Pharm. D.

Frans’ experience spans more than 30 years in the (bio)pharmaceutical industry. He has held staff / senior managerial positions in Strategic Program Development, QA / QP, Project Management, R&D and Regulatory Affairs. Since 1992, he was one of the partners that built the Synthon group of companies (1,500 FTEs at 9 strategic locations globally) and was involved in the R&D, Regulatory Affairs, manufacturing and commercialization of generic medicines, biosimilars and new biological entities.

Founding Partner,
Paul Lelieveld,
Ir., MSc.

Paul’s experience spans more than 25 years in the commercialization of technologies, strategy & business development, M&A, and in selecting, investing and building LifeScience companies; Paul has successfully led investment rounds in several Life science companies for investment funds and family offices.

Founding Partner
Frans van Dalen,
Pharm. D.

Frans’ experience spans more than 30 years in the (bio)pharmaceutical industry. He has held staff / senior managerial positions in Strategic Program Development, QA / QP, Project Management, R&D and Regulatory Affairs. Since 1992, he was one of the partners that built the Synthon group of companies (1,500 FTEs at 9 strategic locations globally) and was involved in the R&D, Regulatory Affairs, manufacturing and commercialization of generic medicines, biosimilars and new biological entities.

Senior Clinical Expert
Peter Goedings,
Dr.

Peter’s educational background is biochemistry (University Utrecht) and pharmaceutical plant physiology (PhD, University Witten). Peter has an international career in the pharmaceutical industry with focus on clinical drug development in oncology and has held positions as Research Director and Member of the Board of Management at Helixor Heilmittel, Rosenfeld, Germany; Director Global Clinical Development Oncology at Altana Pharma, Konstanz, Germany; and Director Clinical Strategy for newly developed biopharmaceutical drugs Synthon Biopharmaceuticals, Nijmegen.

Intellectual Property Expert,
Mark Buscher.

Mark is a U.S. attorney specialized in patent law. For over 20 years, Mark has been involved with pharmaceutical patent law, including drafting patents and portfolio development as well as developing invalidity and non-infringement solutions, especially for ANDA (Abbreviated New Drug Application) applicants. He has law firm and in-house experience including as Chief Patent Counsel for Synthon Pharmaceuticals, Inc. and later President of Synthon IP, Inc. Currently Mark is the founding member of Buscher Patent PLLC in Manassas, Virginia U.S.A. .

Senior Clinical Expert
Peter Goedings,
Dr.

Peter’s educational background is biochemistry (University Utrecht) and pharmaceutical plant physiology (PhD, University Witten). Peter has an international career in the pharmaceutical industry with focus on clinical drug development in oncology and has held positions as Research Director and Member of the Board of Management at Helixor Heilmittel, Rosenfeld, Germany; Director Global Clinical Development Oncology at Altana Pharma, Konstanz, Germany; and Director Clinical Strategy for newly developed biopharmaceutical drugs Synthon Biopharmaceuticals, Nijmegen.

Intellectual Property Expert,
Mark Buscher.

Mark is a U.S. attorney specialized in patent law. For over 20 years, Mark has been involved with pharmaceutical patent law, including drafting patents and portfolio development as well as developing invalidity and non-infringement solutions, especially for ANDA (Abbreviated New Drug Application) applicants. He has law firm and in-house experience including as Chief Patent Counsel for Synthon Pharmaceuticals, Inc. and later President of Synthon IP, Inc. Currently Mark is the founding member of Buscher Patent PLLC in Manassas, Virginia U.S.A. .

Senior Drug Development & Manufacturing Expert,
Cees Stouten,
MSc.

Cees has an educational background in analytical chemistry, is pertinacious in trouble shooting and has a strong drive to liaise. Cees has a longstanding and deep experience along the entire drug development, manufacturing, and control value chain. Worked more than 20 years for Synthon in various R&D positions, mostly in R&D project Management and in product/process transfers to Contract Manufacturing Organizations.
Currently Cees is Vice President of Chemistry, Manufacturing and Control at Meneldor’s portfolio company Atriva Therapeutics GmbH and Site Manager of Atriva Therapeutics B.V.